Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.

ABSTRACT: Background: Biological agents (also termed biologics or biologicals) play a growingly central role in the treatment of immunological diseases. However, the numerous studies published on biologics complicate the decision on the most appropriate biologic for a given disease. We aim to address this problem by publishing a series of systematic reviews evaluating the safety and efficacy of B cell-targeting biologics for the treatment of immune-mediated diseases. This article assesses the safety and efficacy of atacicept, a recombinant fusion protein consisting of the binding portion of transmembrane activator and CAML interactor (TACI; also known as tumor necrosis factor receptor superfamily member 13B), which is able to bind the cytokines B cell-activating factor (BAFF) and a proliferat

SUBMITTER: Kaegi C 

PROVIDER: S-EPMC7105675 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature